171 related articles for article (PubMed ID: 28941072)
1. Oral melphalan for the treatment of relapsed canine lymphoma.
Mastromauro ML; Suter SE; Hauck ML; Hess PR
Vet Comp Oncol; 2018 Mar; 16(1):E123-E129. PubMed ID: 28941072
[TBL] [Abstract][Full Text] [Related]
2. Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs.
Back AR; Schleis SE; Smrkovski OA; Lee J; Smith AN; Phillips JC
Vet Comp Oncol; 2015 Dec; 13(4):398-408. PubMed ID: 23910023
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
Parsons-Doherty M; Poirier VJ; Monteith G
Can Vet J; 2014 Feb; 55(2):175-80. PubMed ID: 24489398
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience.
Smallwood K; Tanis JB; Grant IA; Blackwood L; Killick DR; Amores-Fuster I; Elliott J; Mas A; Harper A; Marrington M; Finotello R
Vet Comp Oncol; 2019 Jun; 17(2):165-173. PubMed ID: 30666777
[TBL] [Abstract][Full Text] [Related]
5. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.
Alvarez FJ; Kisseberth WC; Gallant SL; Couto CG
J Vet Intern Med; 2006; 20(5):1178-83. PubMed ID: 17063713
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma.
Duckett ME; Curran KM; Bracha S; Leeper HJ
J Am Anim Hosp Assoc; 2024 Jan; 60(1):7-14. PubMed ID: 38175982
[TBL] [Abstract][Full Text] [Related]
7. Dacarbazine as single-agent therapy for relapsed lymphoma in dogs.
Griessmayr PC; Payne SE; Winter JE; Barber LG; Shofer FS
J Vet Intern Med; 2009; 23(6):1227-31. PubMed ID: 19709354
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs.
Fernández R; Chon E
J Vet Intern Med; 2018 May; 32(3):1060-1069. PubMed ID: 29566439
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma.
Treggiari E; Elliott JW; Baines SJ; Blackwood L
Vet Comp Oncol; 2018 Jun; 16(2):194-201. PubMed ID: 28766920
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
Rassnick KM; Bailey DB; Malone EK; Flory AB; Kiselow MA; Intile JL
J Am Anim Hosp Assoc; 2014; 50(3):167-73. PubMed ID: 24659727
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of clinical response and prognostic factors in canine multicentric lymphoma treated with first rescue therapy.
Blaxill JE; Bennett PF
Vet Comp Oncol; 2024 Jun; 22(2):265-277. PubMed ID: 38646859
[TBL] [Abstract][Full Text] [Related]
12. Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014).
Lenz JA; Robat CS; Stein TJ
J Small Anim Pract; 2016 Aug; 57(8):429-34. PubMed ID: 27251593
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013).
Gillem J; Giuffrida M; Krick E
Vet Comp Oncol; 2017 Jun; 15(2):400-410. PubMed ID: 26463827
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma.
Saba CF; Thamm DH; Vail DM
J Vet Intern Med; 2007; 21(1):127-32. PubMed ID: 17338160
[TBL] [Abstract][Full Text] [Related]
15. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.
Moore AS; London CA; Wood CA; Williams LE; Cotter SM; L'Heureux DA; Frimberger AE
J Vet Intern Med; 1999; 13(5):395-8. PubMed ID: 10499719
[TBL] [Abstract][Full Text] [Related]
16. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA
J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378
[TBL] [Abstract][Full Text] [Related]
17. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006).
Bannink EO; Sauerbrey ML; Mullins MN; Hauptman JG; Obradovich JE
J Am Vet Med Assoc; 2008 Aug; 233(3):446-51. PubMed ID: 18673031
[TBL] [Abstract][Full Text] [Related]
18. Combination of Bleomycin and Cytosine Arabinoside Chemotherapy for Relapsed Canine Lymphoma.
Batschinski K; Dervisis N; Kitchell B; Newman R; Erfourth T
J Am Anim Hosp Assoc; 2018; 54(3):150-155. PubMed ID: 29558212
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.
Saba CF; Hafeman SD; Vail DM; Thamm DH
J Vet Intern Med; 2009; 23(5):1058-63. PubMed ID: 19678892
[TBL] [Abstract][Full Text] [Related]
20. Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials.
Saba CF; Clifford C; Burgess K; Phillips B; Vail D; Wright Z; Curran K; Fan T; Elmslie R; Post G; Thamm D
Vet Comp Oncol; 2020 Dec; 18(4):763-769. PubMed ID: 32346934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
